This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Sep 2011

Takeda Initiates Phase III Trials for Type 2 Diabetes Therapy TAK-875

The Japanese pharma has initiated 3 phase III clinical trials, including a multi-center, double-blind controlled trial which will evaluate the efficacy and safety of TAK-875.

Takeda Pharmaceutical announced that TAK-875 has entered into phase III clinical trials for the treatment of type 2 diabetes in Japan. TAK-875 is expected to allow patients with type 2 diabetes to have improved glycemic effects with low risk of inducing hypoglycemia.

 

TAK-875 is an agonist of GPR40, one of the G-protein-coupled receptors(GPCR) expressed in pancreatic islet cells, which has a novel mechanism of action for type 2 diabetes, discovered by Takeda based on its GPCR research. It works by increasing insulin secretion in a glucose-dependent manner, which is different from the mechanisms of sulfonylurea.

 

Takeda has initiated 3 phase III clinical trials, including a multi-center, double-blind controlled trial which will evaluate the efficacy

Related News